Utilisation de la toxine botulique pour le traitement de la spasticité du membre inférieur chez l’enfant : revue de la littérature

Abstract

Botulinum toxin type A has been used for the treatment of children with spastic diplegia since the early 90's. The efficacy and safety of this medication have been proved by a large number of studies published in the scientific literature. Spasticity tends to produce more negative than positive effects. A severe spasticity can limit range of motion and interfere with daily living activities. Children with cerebral palsy often develop muscular contractures and bone deformities during growth. These represent secondary problems related to the brain lesion. Spasticity treatment is indicated in order to avoid the development of orthopedic problems and to preserve quality of life. An extensive review of the literature has been conducted in order to update knowledge and to enhance the importance of several aspects regarding botulinum treatment indications.